Regeneron Pharmaceuticals (REGN) to Release Earnings on Thursday

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) will be issuing its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $8.07 per share for the quarter. Persons interested in participating in the company's earnings conference call can do so using this link.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company had revenue of $3.43 billion during the quarter, compared to analysts' expectations of $3.29 billion. During the same period last year, the firm earned $10.96 EPS. The firm's revenue for the quarter was up .6% on a year-over-year basis. On average, analysts expect Regeneron Pharmaceuticals to post $39 EPS for the current fiscal year and $40 EPS for the next fiscal year.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $15.86 during mid-day trading on Thursday, reaching $890.68. 574,971 shares of the company were exchanged, compared to its average volume of 490,896. The firm's 50-day simple moving average is $949.30 and its two-hundred day simple moving average is $893.27. The firm has a market cap of $97.76 billion, a PE ratio of 25.63, a price-to-earnings-growth ratio of 2.61 and a beta of 0.11. Regeneron Pharmaceuticals has a twelve month low of $684.80 and a twelve month high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69.

Insider Buying and Selling

In other news, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the sale, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Bonnie L. Bassler sold 827 shares of the company's stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total value of $793,093.00. Following the transaction, the director now directly owns 1,382 shares in the company, valued at $1,325,338. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at $12,888,716.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 11,022 shares of company stock valued at $10,552,991. 8.83% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on REGN. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an "outperform" rating in a research report on Monday, February 5th. Barclays increased their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an "overweight" rating in a report on Tuesday, January 23rd. StockNews.com cut shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 20th. Royal Bank of Canada restated an "outperform" rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. Finally, TD Cowen upped their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a "buy" rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $977.77.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.